急性リンパ性白血病 (Acute Lymphoblastic Leukemia) とは,急性リンパ性白血病 (Acute Lymphoblastic Leukemia) とは,急性リンパ性白血病 (Acute
Ching-Hon Pui1, Leslie L Robison, A Thomas Look
1Department of Oncology, St Jude Children's Research Hospital and University of Tennessee Health Science Center, Memphis, TN 38105, USA. ching-hon.pui@stjude.org
Lancet (London, England)
|March 25, 2008
まとめ
急性リンパ性白血病 (ALL) は,子供と成人に影響します. 研究は,治療率を高め,副作用を軽減するために,標的型療法と改善された治療法に焦点を当てています.
科学分野:
- 血液学 ヘマトロジ
- 小児腫瘍学 小児腫瘍学
- 分子生物学は分子生物学である.
背景:
- 急性リンパ性白血病 (ALL) は,子供および成人における一般的なリンパ原細胞悪性腫瘍です.
- 現在の治療法では,小児の治癒率が80%以上に達しますが,有毒性があります.
- ALLの病理生物学を理解することは,毒性が低く,より効果的な治療法を開発するために不可欠です.
研究 の 目的:
- 副作用を最小限に抑えながら生存率の上昇を維持するALLの革新的な治療戦略を探求する.
- 白血病細胞の遺伝的欠陥に基づく分子標的療法の可能性を調査する.
- 大人および高リスクの小児ALLサブグループにおける治癒率を改善するために.
主な方法:
- 小児および成人ALLにおける現在の治療結果と毒性のレビュー.
- 新興分子技術の分析とALL病理生物学への応用.
- ALLの起源,危険因子,および新しい治療法に関する研究が進行中です.
主要な成果:
- 高度な治癒率 (>80%) は,小児ALLにおいて,集中的な治療法で達成可能である.
- 分子学的進歩は,特定の遺伝的欠陥に対する標的治療の可能性を秘めています.
- 大人および高リスクの小児ALL集団は,依然として最適な治療率を下回っています.
結論:
- 標的治療は,特定の遺伝的欠陥に対処することによって,ALLの管理に革命をもたらすことを約束しています.
- 大人および高リスク小児ALLの治療を最適化するためにさらなる研究が必要です.
- 毒性の低下と有効性のバランスをとることは,将来のALL治療戦略の重要な目標です.
関連する概念動画
01:27Disorders of Leukocytes
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
01:23Cells of the Adaptive Immune Response
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
01:22Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:16Primary Lymphoid Organs
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...